Literature DB >> 6438225

Nomifensine in hyperprolactinemic states.

E E Müller, F Camanni, A R Genazzani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6438225     DOI： 10.1007/BF03351028

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  8 in total

1.  A new pharmacological approach to the diagnosis of hyperprolactinaemic states: the nomifensine test.

Authors:  A R Genazzani; F Camanni; F Massara; E Picciolini; D Cocchi; L Belforte; E E Müller
Journal:  Acta Endocrinol (Copenh)       Date:  1980-02

2.  Nomifensine, TRH and insulin-induced hypoglycemia tests in the diagnosis of prolactinomas.

Authors:  F Iannotta; P Fachinetti; A Fachinetti; G Pinotti; L Usellini
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

3.  Prolactin responsiveness to nomifensine in patients with hyperprolactinemia of tumorous or uncertain etiology.

Authors:  F Camanni; A R Genazzani; F Massara; V de Leo; G M Molinatti; E E Müller
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

4.  Comparison of the responses in the nomifensine test with hyperprolactinemia due to prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors.

Authors:  K Kamoi; I Tchuchida; H Sato; R Tanaka; T Ishiguro; K Kaneko; Y Iwasaki; A Shibata
Journal:  J Clin Endocrinol Metab       Date:  1981-12       Impact factor: 5.958

5.  Effect of central nervous system dopaminergic activation on prolactin secretion in man: evidence for a common central defect in hyperprolactinemic patients with and without radiological signs of pituitary tumors.

Authors:  P G Crosignani; C Ferrari; A Malinverni; C Barbieri; A M Mattei; R Caldara; M Rocchetti
Journal:  J Clin Endocrinol Metab       Date:  1980-11       Impact factor: 5.958

6.  Nomifensine: diagnostic test in hyperprolactinemic states.

Authors:  E E Müller; A R Genazzani; S Murru
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

7.  Failure of nomifensine administration to discriminate between tumorous and nontumorous hyperprolactinemia.

Authors:  C Ferrari; P G Crosignani; R Caldara; M C Picciotti; A Malinverni; B Barattini; P Rampini; P Telloli
Journal:  J Clin Endocrinol Metab       Date:  1980-01       Impact factor: 5.958

8.  Evaluation of two inhibitory tests (nomifensine and L-dopa + carbidopa) for the diagnosis of hyperprolactinaemic states.

Authors:  P Moriondo; P Travaglini; M Nissim; G Faglia
Journal:  Clin Endocrinol (Oxf)       Date:  1980-12       Impact factor: 3.478
  8 in total
  1 in total

1.  More on nomifensine.

Authors:  A Liuzzi; P G Chiodini
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.